H. 

TL!

2

ð

1

UTILITY
PATENT APPLICATION
TRANSMITTAL

Please type a plus sign (+) inside this box

Attorr	ney Docket No.	B185 US CP DV1					
First Inventor		BROWNING, JEFFREY L.					
Title	ANTI-LYMPHOTOXIN-BETA RECEPTOR						
Evara	oo Mail Labal Ne	EL543620901US					

(Only for new nonprovisional applications under 37 CFR 1.53(b)) Express Mail Label No. Assistant Commissioner for Patents APPLICATION ELEMENTS ADDRESS TO: **Box Patent Application** See MPEP chapter 600 concerning utility patent application contents. Washington, DC 20231 Fee Transmittal Form (e.g., PTO/SB/17) CD-ROM or CD-R in duplicate, large table or (Submit an original and a duplicate) Computer Program (Appendix) Applicant claims small entity status. 8. Nucleotide and/or Amino Acid Sequence Submission See 37 CFR 1.27. (if applicable, all necessary) Specification [Total Pages 3. **X** Computer Readable Form (CRF) (preferred arrangement set forth below) - Descriptive title of the invention Specification Sequence Listing on: - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D i. CD-ROM or CD-R (2 copies); or - Reference to sequence listing, a table, i i. 🔲 paper or a computer program listing appendix - Background of the Invention Statements verifying identity of above copies - Brief Summary of the Invention ACCOMPANYING APPLICATION PARTS - Brief Description of the Drawings (if filed) - Detailed Description Assignment Papers (cover sheet & document(s)) - Claim(s) 37 CFR 3.73(b) Statement Power of - Abstract of the Disclosure Attorney (when there is an assignee) English Translation Document (if applicable) 4. **X** Drawing(s) (35 U.S.C. 113) [ Total Sheets Copies of IDS Information Disclosure 5. Oath or Declaration [ Total Pages Statement (IDS)/PTO-1449 Citations Newly executed (original or copy) Copy from a prior application (37 CFR 1.63 (d)) 13 **Preliminary Amendment** Return Receipt Postcard (MPEP 503) (for continuation/divisional with Box 18 completed) (Should be specifically itemized) Certified Copy of Priority Document(s) (if foreign priority is claimed) DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR Request and Certification under 35 U.S.C. 122 1.63(d)(2) and 1.33(b). (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent I.P.E.A. Amended Claim Application Data Sheet. See 37 CFR 1.76 17. 🗶 Other: Sheets (9 pp) 18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: 08/875,560 Continuation X Divisional Continuation-in-part (CIP) of prior application No.:  $_{\textit{Examiner}\_}G.$  Bansal Prior application information: For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. 19. CORRESPONDENCE ADDRESS Customer Number or Bar Code Label X Correspondence address below (Insert Customer No. or Attach bar code label here) Name Niki D. Cox BIOGEN, INC. 14 Cambridge Center Address City State Cambridge MA Zip Code 02142 Country Telephone (617) 679-2079 **USA** Fax 7) 679-2838 Niki D. Cox Name (Print/Type) Registration No. (Attorney/Agent) 42,446 8/16/01

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

PTO/SB/17 (09-00)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## **FEE TRANSMITTAL** for FY 2001

Patent fees are subject to annual revision.

**TOTAL AMOUNT OF PAYMENT** 

(\$)	1,	21	4
` ' '			

Complete if Known					
Application Number	UNASSIGNED (Div. of 08/87				
Filing Date	HEREWITH				
First Named Inventor	BROWNING, JEFFREY L.				
Examiner Name	G. Bansal				
Group Art Unit	1642				
Attorney Docket No.	B185 US CP DV1				

METHOD O	METHOD OF PAYMENT FEE CALCULATION (continued)								
1. The Commissioner is he indicated fees and cred	ereby authorized to charge	3. ADDITIONAL FEES Large Entity Small Entity							
Deposit	at any overpayments to:	Fee	Fee	Fee	Fee	•	Description	n	Fee Paid
Account Number 02-2327		Code 105	( <b>\$</b> ) 130	205	e (\$) 65	Surcharge - late f	•	ı	100114114
Deposit Account						_	Ŏ		
Name		127	50	227	25	Surcharge - late p cover sheet	provisional fili	ng fee or	
Charge Any Additional Fee R Under 37 CFR 1.16 and 1.17		139	130	139	130	Non-English spec	ification		
Applicant claims small entity		147 2	2,520	147	2,520	For filing a reque	st for ex parte	reexamination	
See 37 CFR 1.27		112	920*	112	920*	Requesting public Examiner action	cation of SIR	prior to	
2. Payment Enclosed:	. Money —	113 1	.840*	113	1.840	Requesting public	cation of SIR	after	
Check Credit car	rd Order Other			045		Examiner action			,
FEE CALC	CULATION			215	55 105	Extension for rep	•		-
1. BASIC FILING FEE			390 890	216 217		Extension for repl	•		
Large Entity Small Entity Fee Fee Fee Fee Fee	- December	118 1				Extension for repl	•		
Code (\$) Code (\$)	e Description Fee Paid					Extension for repl	•		
101 710 201 355 Utility	y filing fee 710	128 1	•			Extension for repl	ly within titth	month	
106 320 206 160 Desig	gn filing fee			219		Notice of Appeal			
107 490 207 245 Plant	filing fee		310	220		Filing a brief in su	• •	ppeai	
108 710 208 355 Reiss	sue filing fee			221		Request for oral h	•		
114 150 214 75 Provis	sional filing fee	138 1	-	138 1		Petition to institute		- 1	
SUB.	TOTAL (1) (\$) 710			240	55	Petition to revive			
2. EXTRA CLAIM FEES	τοιλε(ι) [(Ψ)	141 1				Petition to revive		nl	
	Fee from	142 1 143		242		Utility issue fee (o Design issue fee	or reissue)		
[ [ [ 77]	ra Claims below Fee Paid			244		Plant issue fee			
Independent 2 - 3** =	13 X 18 = 234 0 X = 0			122		Petitions to the Co	ommissioner		
Claims LL  Multiple Dependent	270 = 270	123	50	123	50	Petitions related to		annlications	
	270 - 273		240	126		Submission of Infe	•		
Large Entity Small Entity									
Fee Fee Fee Fee F Code (\$) Code (\$)	ee Description	581	40	581	40	Recording each p property (times no			
	ns in excess of 20	146	710	246	355	Filing a submissio (37 CFR § 1.129(	on after final r	ejection	
1	pendent claims in excess of 3	149	710	249	355	For each addition		o be	
	tiple dependent claim, if not paid					examined (37 CF	R § 1.129(b)	)	
	eissue independent claims er original patent	179	710	279	355	Request for Cont	inued Examir	nation (RCE)	
110 18 210 9 **Re an	eissue claims in excess of 20 nd over original patent	169	900	169	900	Request for expe of a design applic		ation	
SUBTOT	(t) 504	Other fo	ee (sp	ecify)				l	
**or number previously paid, if g	(2) L.	Reduce	ed by I	Basic	Filing F	ee Paid S	SUBTOTAL	(3)	0
SUBMITTED BY	777		_	-			Complete (if	annlicable)	
Name (Print/Type)	Niki D. Cox		egistra			42,446	Telephone	(617) 67	79-2079
Signature	In I in Conf	(At	torneyl	Agent)	-	72,770	Date		
	mun ay						Date	8/16/	9

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Docket No. B185 US CP DV1

Applicant: BROWNING, Jeffrey L. et al.

Serial No.: UNASSIGNED (Div. of 08/875,560

Filing Date: HEREWITH

For: ANTI-LYMPHOTOXIN-BETA RECEPTOR ANTIBODIES AS ANTI-TUMOR AGENTS

## CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence:  Divisional Application Transmittal (1pg), Fee Transmittal Form (1 pg), copy of Specification with Drawings (91pp), Preliminary Amendment (11 pp), Amended Declaration (4 pp), Power
of Attorney (1 pg), PCT IPEA Amended Claim Sheets (9 pp), return postcard
is being deposited with the United States Postal Service under 37 CFR 1.10 as Express Mail
Label No. EL543620901US in an envelope addressed to:
BOX PATENT APPLICATION

Assistant Commissioner for Patents Washington, D.C. 20231

on August 16, 2001

Date

Patricia Hofstetter